Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 26, 2019--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors, today announced that the company will present nonclinical data on PEN-221 at the 2019 American Association for Cancer Research (AACR) Annual Meeting, occurring March 29 – April 3, 2019 in Atlanta, GA.
PEN-221 is a miniature drug conjugate designed to rapidly penetrate deep into solid tumors where it is highly selective for somatostatin receptor 2 (SSTR2) and accumulates its potent DM1 cytotoxic payload. The presenter will demonstrate the effectiveness of PEN-221 in combination with epigenetic modulation by an HDAC inhibitor in nonclinical models of human cancer. The data show that an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy.
Details of the poster presentation are as follows:
Title: Epigenetic modulation of SSTR2 expression provides the potential to broaden PEN-221 treatment population
Date: Tuesday, April 2, 2019
Time: 1:00pm Eastern Time
Location: Georgia World Congress Center, Atlanta, GA
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors. PEN-221 is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors. PEN-221 is highly selective for SSTR2 and is designed to rapidly penetrate deep into solid tumors where it accumulates and releases its potent DM1 payload over time within the tumor cells. Tarveda is also advancing its HSP90 binding drug conjugate platform with lead drug candidate PEN-866, which selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38. The safety and efficacy of PEN-866 in patients with cancer is currently being evaluated in a clinical trial. Tarveda’s strategy includes developing its own proprietary miniature drug conjugates as well as applying its miniature drug conjugate platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarvedatx.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005331/en/
CONTACT: Amanda Houlihan
781 235 3060
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Tarveda Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 03/26/2019 08:00 AM/DISC: 03/26/2019 08:00 AM